BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

Backed by Hillhouse’s deep pockets, Overland aims to leverage its parent firm’s biopharma ecosystem in China to bring first-in-class and best-in-class Western therapies to the country. Overland Pharmaceuticals launched...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Inhibition of fungal splicing factor PRPF8 for cryptococcal infection

DISEASE CATEGORY: Infectious disease INDICATION: Fungal infection Small molecule inhibitors of a Cryptococcus spp. intein-containing intron splicing factor PRPF8 could treat infections by Cryptococcus neoformans. A screen of 300 small molecules yielded a carboxamide-based compound that inhibited PRPF8...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

Allogene has found its gateway to China via a deal with Hillhouse-backed Overland that gives the newly launched China company its second partner and an allogeneic CAR T cell platform. The news came...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

BMS is looking to diversify beyond its heavy reliance on its cancer portfolio through a $13.1 billion takeout of cardiovascular company MyoKardia. For MyoKardia Inc. (NASDAQ:MYOK), the $225 per share acquisition price is a 61%...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...
Items per page:
1 - 10 of 501
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

Backed by Hillhouse’s deep pockets, Overland aims to leverage its parent firm’s biopharma ecosystem in China to bring first-in-class and best-in-class Western therapies to the country. Overland Pharmaceuticals launched...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Inhibition of fungal splicing factor PRPF8 for cryptococcal infection

DISEASE CATEGORY: Infectious disease INDICATION: Fungal infection Small molecule inhibitors of a Cryptococcus spp. intein-containing intron splicing factor PRPF8 could treat infections by Cryptococcus neoformans. A screen of 300 small molecules yielded a carboxamide-based compound that inhibited PRPF8...
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

As Arcus becomes the second company to report clinical data for a CD73 inhibitor in pancreatic cancer behind front-runner AstraZeneca, at least six more teams have early-stage clinical programs targeting the immuno-metabolism modulating receptor. An...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

Allogene has found its gateway to China via a deal with Hillhouse-backed Overland that gives the newly launched China company its second partner and an allogeneic CAR T cell platform. The news came...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

BMS is looking to diversify beyond its heavy reliance on its cancer portfolio through a $13.1 billion takeout of cardiovascular company MyoKardia. For MyoKardia Inc. (NASDAQ:MYOK), the $225 per share acquisition price is a 61%...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...
Items per page:
1 - 10 of 501